Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
The drug is priced at Rs 2000 for a course of 40 tablets
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Subscribe To Our Newsletter & Stay Updated
